viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals makes good progress with Clevegen immunotherapy trial


  • First-in-person trial underway for Clevegen cancer treatment
  • Patients dosed showed a rise in natural killer cells and T-Cells
  • Patient’s tumour shrank after treatment
  • Clevegen may be able to reactivate T-Cells in cancer sufferers

Quick facts: Faron Pharmaceuticals Ltd

Price: 286.7 GBX

Market: AIM
Market Cap: £124.11 m


How is it doing

Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.

Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.

Clevegen has been designed to recognise cancer and break the cell’s protective shell.

The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.

Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.


Clevegen has helped the company rebuild after a major disappointment with another drug Traumakine.

A phase III trial as a treatment for lung inflammation condition ARDS missed its target and there was no benefit against the placebo.

Faron (LON:FARN) is working with drug regulators to work out why the results were poor and is confident Traumakine can be of benefit to some patients.


What the boss says: Markku Jalkanen, CEO

“We are thrilled with the progress the MATINS [Clevegen] study has made during the last few months.
“We believe we have the first macrophage immune checkpoint drug in clinical development promoting immune activation and are encouraged by the latest data indicating potential early efficacy and good tolerability.
“We expect to progress the cohort expansion phase of the study in Q3 2019 in patients with late-stage colorectal cancer.”



Inflection points

• In October, Faron said its Clevegen treatment could potentially induce a "stronger immune response" at lower doses, increasing its safety margins
• Faron finds a partner from the many said to be watching MATINS trial data
• Shares doubled since results from MATINS trial started to be released
• Traumakine reboots as a treatment for a specific type of ARDS sufferer who has a special type of genetic mutation known as C/T.


Blue Sky

If Clevegen proves to a way of re-awakening T-cells in metastatic tumours, the potential as an immunotherapy treatment is enormous
Traumakine is a smaller opportunity now but still substantial for Faron
Before the Traumakine trial result, the shares almost reached 900p.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



Investor Update: ImmuPharma lands licensing deal for Lupuzor

Headlines from the Proactive UK newsroom. ImmuPharma (LON:IMM) has signed an exclusive licence and development agreement with Avion Pharmaceuticals for its Lupus treatment Lupuzor.  Avion will fund a new international Phase III trial up to a cost of US$25mln and commercialise the...

1 week, 4 days ago


Second Price Monitoring Extn

6 days, 23 hours ago

Price Monitoring Extension

6 days, 23 hours ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago


1 week, 3 days ago

Second Price Monitoring Extn

1 week, 4 days ago

Price Monitoring Extension

1 week, 4 days ago

2 min read